KRAS
| 3 min read
A new blood test focusing on KRAS mutations found evidence of pancreatic cancer recurrence before standard testing.
| 4 min read
Results from Johns Hopkins show a synthetic peptide vaccine was safe and activated mutant-KRAS-specific T cells in 90 percent of participants, offering an early signal that cancer interception may be possible before disease develops.
Page 1 of 1 - 2 Total Items
